+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Therapeutics: Global Markets- Product Image
Lung Cancer Therapeutics: Global Markets- Product Image
New

Lung Cancer Therapeutics: Global Markets

  • PDF Icon

    Report

  • 209 Pages
  • March 2026
  • Region: Global
  • BCC Research
  • ID: 6233818
Description Jump to:
The global market for lung cancer therapeutics is expected to grow from $32.5 billion in 2025 and is projected to reach $49.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.8% during the forecast period of 2025 to 2030.

Lung cancer, or lung carcinoma, is a type of cancer that affects lung tissues and is characterized by the presence of abnormal cell division and rapid growth of lung tissue. Globally, lung cancer is a leading cause of cancer death and poses a significant therapeutic burden with poor survival rates. According to estimates from the American Cancer Society, lung cancer is the second-most commonly diagnosed cancer type and has the highest mortality rate of any cancer in the U.S. Cigarette smoking is considered to be the primary cause of lung cancer. Pipe and cigar smoking, passive smoking or secondhand smoking, asbestos fibers, radon gas and air pollution are some other causes of lung cancer.

Most primary lung carcinomas originate from the epithelial cells that line the surface of the airways. NSCLC and SCLC are the two main histopathological subtypes of lung cancer. NSCLC further encompasses three primary subtypes: large-cell carcinoma, squamous-cell carcinoma and adenocarcinoma. It is the most common type. In contrast, SCLC represents a smaller proportion.

The lung cancer therapeutics market is rapidly evolving due to the rising number of lung cancer cases, increasing innovation in lung cancer therapeutics, substantial R&D spending by market players, a surge in government funding, and significant pharmaceutical R&D expenditures. Market pressures include rising generic competition and patent expirations, a shortage of oncology professionals, and the availability of low-priced chemotherapeutics, which limits the growth of advanced therapies. Lung cancer therapeutics include traditional chemotherapies, advanced targeted therapies, and the most innovative immunotherapies. Keytruda, the highest-selling drug in the entire oncology market, is a prime example of this value.

Report Scope

This report will provide detailed information on lung cancer therapeutics. This report analyzes the market trends for lung cancer therapeutics, providing data for 2024, estimates for 2025, projections of compound annual growth rates (CAGRs) through 2030 (forecast period: 2025-2030) and regional markets for lung cancer therapeutics. This report will highlight the current and future market potential of lung cancer therapeutics, providing a detailed analysis of the competitive environment. The report will cover regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key market players.

In this report, the market is segmented by cancer type into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By therapeutic type, the market is segmented into targeted therapy, chemotherapy and immunotherapy.

The market has been segmented into five regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. This report will also provide detailed analyses of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. For market estimates, data will be provided for 2024, given the base year, along with data for 2025 and a forecast value for 2030.

The report aims to:

  • Analyze types of lung cancer therapeutics.
  • Analyze global market size and segments.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts for 2030.
  • Assess market shares, competitiveness and industry structure.
  • Identify potential long-term impacts on the lung cancer therapeutics market.

The report includes:

  • 86 data tables and 55 additional tables
  • An overview of the global market for lung cancer therapeutics
  • In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
  • Evaluation of the current market size and revenue growth prospects specific to the lung cancer therapeutics, accompanied by a market share analysis by type, therapeutics, and region
  • Analysis of current and future demand in the lung cancer therapeutics market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
  • Analysis of drivers, challenges, and opportunities affecting market growth
  • Coverage of evolving technologies, the current and future market potential, R&D activities, clinical trials, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
  • Market share analysis of the key market participants in the industry, along with their research priorities, product portfolios, global rankings and company competitive landscape
  • Profiles of major companies within the industry, including AstraZeneca, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Co., and Pfizer Inc.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion
Chapter 2 Market Overview
  • Overview
  • Macroeconomic Factors Analysis
  • Impact of U.S. Tariffs on the Pharmaceutical Industry
  • Healthcare Expenditure
  • Geopolitical Risks, Trade Wars and Supply Chain Disruptions
  • Impact of Global Economic Growth (GDP) on the Pharma Sector
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Competitiveness in the Industry
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Rising Lung Cancer Cases
  • Increasing Innovation in Lung Cancer Therapeutics
  • Increasing R&D Spending by Market Players
  • Rise in Government Funding and Pharmaceutical R&D Spending
  • Market Restraints
  • Rising Generic Competition and Patent Expiration
  • Shortage of Oncology Professionals
  • Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
  • Market Opportunities
  • Increasing Demand for Novel Therapies
  • Emerging Markets
  • Increasing Lung Cancer Incidence Among Non-Smokers
Chapter 4 Regulatory Landscape
  • Overview
  • U.S.
  • Europe
  • Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
  • Overview
  • Artificial Intelligence
  • Immunotherapies and Cell Therapy
  • Emergent Biomarkers
  • Clinical Trial Analysis
  • Clinical Trials Analysis by Type of Study
  • Clinical Trials Analysis by Status
  • Clinical Trials Analysis by Phase
  • Key Takeaways
  • Patent Analysis
  • Key Takeaways
Chapter 6 Market Segment Analysis
  • Segmentation Breakdown
  • Global Market for Lung Cancer Therapeutics, by Cancer Type
  • Key Takeaways
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Global Market for Lung Cancer Therapeutics, by Therapeutic
  • Key Takeaways
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Geographic Breakdown
  • Global Market for Lung Cancer Therapeutics, by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
Chapter 7 Competitive Intelligence
  • Key Takeaways
  • Competitive Landscape
  • Company Share Analysis
  • Strategic Analysis
Chapter 8 Sustainability in the Global Market for Lung Cancer Therapeutics: An ESG Perspective
  • Introduction to ESG
  • Sustainability in the Lung Cancer Therapeutics Market
  • ESG Perspective
  • Environmental Impact
  • Social Impact
  • Governance Impact
  • ESG Risk Ratings
  • Conclusion
Chapter 9 Appendix
  • Methodology
  • Abbreviations
  • Sources
  • Company Profiles
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • JAZZ PHARMACEUTICALS INC.
  • JOHNSON & JOHNSON
  • LILLY USA LLC.
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Emerging Players/Market Disruptors
List of Tables
Summary Table: Global Market for Lung Cancer Therapeutics, by Region, Through 2030
Table 1: Health Expenditure, by Country, 2021-2023
Table 2: Lung Cancer Statistics, by Region 2022 and 2023
Table 3: NCI Funding, by Mechanism, 2020-2024
Table 4: Selected Approved Biosimilars in the Market
Table 5: Clinical Trials in Lung Cancer Therapeutics, by Type of Study, as of November 2025
Table 6: Clinical Trials in Lung Cancer Therapeutics, by Status, as of November 2025
Table 7: Clinical Trials in Lung Cancer Therapeutics, by Phase, as of November 2025
Table 8: List of Selected Lung Cancer Therapeutics Clinical Trial Studies, 2025
Table 9: List of Selected Recently Granted Patents Related to Lung Cancer Therapeutics, 2024-2025
Table 10: Global Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 11: Global Market for NSCLC in Lung Cancer Therapeutics, by Region, Through 2030
Table 12: Global Market for SCLC in Lung Cancer Therapeutics, by Region, Through 2030
Table 13: Global Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 14: Selected Approved Targeted Therapies in the Lung Cancer Therapeutics Market
Table 15: Global Market for Targeted Therapy in Lung Cancer Therapeutics, by Region, Through 2030
Table 16: Selected Approved Chemotherapies in the Lung Cancer Therapeutics Market
Table 17: Global Market for Chemotherapy in Lung Cancer Therapeutics, by Region, Through 2030
Table 18: Selected Approved Immunotherapies in the Lung Cancer Therapeutics Market
Table 19: Global Market for Immunotherapy in Lung Cancer Therapeutics, by Region, Through 2030
Table 20: Global Market for Lung Cancer Therapeutics, by Region, Through 2030
Table 21: North American Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 22: North American Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 23: North American Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 24: U.S. Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 25: U.S. Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 26: Canadian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 27: Canadian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 28: Mexican Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 29: Mexican Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 30: European Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 31: European Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 32: European Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 33: German Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 34: German Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 35: U.K. Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 36: U.K. Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 37: French Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 38: French Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 39: Italian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 40: Italian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 41: Spanish Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 42: Spanish Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 43: Rest of Europe Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 44: Rest of Europe Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 45: Lung Cancer Cases in Asia-Pacific, by Region, 2022
Table 46: Asia-Pacific Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 47: Asia-Pacific Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 48: Asia-Pacific Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 49: Chinese Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 50: Chinese Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 51: Japanese Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 52: Japanese Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 53: Indian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 54: Indian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 55: South Korean Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 56: South Korean Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 57: Australian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 58: Australian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 59: Rest of Asia-Pacific Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 60: Rest of Asia-Pacific Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 61: MEA Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 62: MEA Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 63: MEA Market for Lung Cancer Therapeutics, by Sub-Region, Through 2030
Table 64: Middle Eastern Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 65: Middle Eastern Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 66: African Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 67: African Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 68: South American Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 69: South American Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 70: South American Market for Lung Cancer Therapeutics, by Country, Through 2030
Table 71: Brazilian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 72: Brazilian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 73: Argentine Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 74: Argentine Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 75: Rest of South America Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
Table 76: Rest of South America Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
Table 77: Key Strategic Initiatives in Lung Cancer Therapeutics Market, 2024-2025
Table 78: Key Focus Areas in ESG Metrics
Table 79: ESG Rankings for Leading Companies in Lung Cancer Therapeutics, 2025*
Table 80: Abbreviations Used in this Report
Table 81: Report Sources
Table 82: AbbVie Inc.: Company Snapshot
Table 83: AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 84: AbbVie Inc.: Product Portfolio
Table 85: AbbVie Inc.: News/Key Developments, 2025
Table 86: Amgen Inc.: Company Snapshot
Table 87: Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 88: Amgen Inc.: Product Portfolio
Table 89: Amgen Inc.: News/Key Developments, 2023-2025
Table 90: AstraZeneca: Company Snapshot
Table 91: AstraZeneca: Financial Performance, FY 2023 and 2024
Table 92: AstraZeneca: Product Portfolio
Table 93: AstraZeneca: News/Recent Developments, 2022-2025
Table 94: Boehringer Ingelheim International GmbH: Company Snapshot
Table 95: Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
Table 96: Boehringer Ingelheim International GmbH: Product Portfolio
Table 97: Boehringer Ingelheim International GmbH: News/Key Developments, 2025
Table 98: Bristol-Myers Squibb Co.: Company Snapshot
Table 99: Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 100: Bristol-Myers Squibb Co.: Product Portfolio
Table 101: Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 102: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 103: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 104: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 105: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 106: Jazz Pharmaceuticals Inc.: Company Snapshot
Table 107: Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 108: Jazz Pharmaceuticals Inc.: Product Portfolio
Table 109: Jazz Pharmaceuticals Inc.: News/Key Developments, 2025
Table 110: Johnson & Johnson: Company Snapshot
Table 111: Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 112: Johnson & Johnson Services Inc.: Product Portfolio
Table 113: Johnson & Johnson Services Inc.: News/Key Developments, 2022-2025
Table 114: Lilly USA LLC.: Company Snapshot
Table 115: Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 116: Lilly USA LLC.: Product Portfolio
Table 117: Lilly USA LLC.: News/Key Development, 2022-2025
Table 118: Merck & Co. Inc.: Company Snapshot
Table 119: Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 120: Merck & Co. Inc.: Product Portfolio
Table 121: Merck & Co. Inc.: News/Key Developments, 2022-2025
Table 122: Novartis AG: Company Snapshot
Table 123: Novartis AG: Financial Performance, FY 2023 and 2024
Table 124: Novartis AG: Product Portfolio
Table 125: Novartis AG: News/Key Developments, 2022
Table 126: Pfizer Inc.: Company Snapshot
Table 127: Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 128: Pfizer Inc.: Product Portfolio
Table 129: Pfizer Inc.: News/Key Developments, 2023-2025
Table 130: Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 131: Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 132: Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 133: Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
Table 134: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 135: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 136: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 137: Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 138: Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 139: Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 140: A Few Emerging Players in the Lung Cancer Therapeutics Market
List of Figures
Summary Figure: Global Market Shares of Lung Cancer Therapeutics, by Region, 2024
Figure 1: Porter’s Five Forces Analysis of the Lung Cancer Therapeutics Market
Figure 2: Market Dynamics of Lung Cancer Therapeutics
Figure 3: Global Shares of Five-Year Prevalence Cases of Lung Cancer, by Region, 2022
Figure 4: Global Market Shares of Companies’ R&D Expenditure, by Function, 2022
Figure 5: Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 6: Global Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 7: Global Market Shares of NSCLC in Lung Cancer Therapeutics, by Region, 2024
Figure 8: Global Market Shares of SCLC in Lung Cancer Therapeutics, by Region, 2024
Figure 9: Global Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 10: Global Market Shares of Targeted Therapy in Lung Cancer Therapeutics, by Region, 2024
Figure 11: Global Market Shares of Chemotherapy in Lung Cancer Therapeutics, by Region, 2024
Figure 12: Global Market Shares of Immunotherapy in Lung Cancer Therapeutics, by Region, 2024
Figure 13: Global Market Shares of Lung Cancer Therapeutics, by Region, 2024
Figure 14: North American Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 15: North American Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 16: North American Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 17: U.S. Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 18: U.S. Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 19: Canadian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 20: Canadian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 21: Mexican Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 22: Mexican Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 23: European Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 24: European Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 25: European Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 26: German Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 27: German Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 28: U.K. Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 29: U.K. Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 30: French Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 31: French Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 32: Italian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 33: Italian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 34: Spanish Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 35: Spanish Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 36: Rest of Europe Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 37: Rest of Europe Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 38: Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 39: Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 40: Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 41: Chinese Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 42: Chinese Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 43: Japanese Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 44: Japanese Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 45: Indian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 46: Indian Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 47: South Korean Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 48: South Korean Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
Figure 49: Australian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 50: Australian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 51: Rest of Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 52: Rest of Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 53: MEA Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 54: MEA Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 55: MEA Market Shares of Lung Cancer Therapeutics, by Sub-Region, 2024
Figure 56: Middle Eastern Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 57: Middle Eastern Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 58: African Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 59: African Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 60: South American Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 61: South American Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 62: South American Market Shares of Lung Cancer Therapeutics, by Country, 2024
Figure 63: Brazilian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 64: Brazilian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 65: Argentine Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 66: Argentine Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 67: Rest of South America Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
Figure 68: Rest of South America Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
Figure 69: Top 10 Blockbuster Lung Cancer Therapeutics, by Sales Revenue, 2023-2024
Figure 70: Global Market Shares of Lung Cancer Therapeutics, by Company, 2024
Figure 71: Pillars of ESG
Figure 72: Advantages of ESG for Companies
Figure 73: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 74: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 75: Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 76: Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 77: AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 78: AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 79: Boehringer Ingelheim International GmbH: Revenue Shares, by Business Unit, FY 2024
Figure 80: Boehringer Ingelheim International GmbH: Revenue Shares, by Region, FY 2024
Figure 81: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 82: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 83: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 84: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 85: Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 86: Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 87: Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 88: Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 89: Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
Figure 90: Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
Figure 91: Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 92: Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 93: Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 94: Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 95: Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 96: Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 97: Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 98: Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 99: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 100: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 101: Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2024

Companies Mentioned

  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Jazz Pharmaceuticals Inc.
  • Johnson & Johnson
  • Lilly Usa LLC.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages209
PublishedMarch 2026
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 32.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 49.5 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Small Cell Lung Cancer Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Small Cell Lung Cancer Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Small Cell Lung Cancer Therapeutics Market Report 2026 - Product Image

Small Cell Lung Cancer Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
China Lung Cancer Therapeutics Market Size, Share and Trends Analysis Report by Disease Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), Therapeutic Class (Chemotherapy, Immunotherapy) 2024-2030 - Product Image

China Lung Cancer Therapeutics Market Size, Share and Trends Analysis Report by Disease Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), Therapeutic Class (Chemotherapy, Immunotherapy) 2024-2030

  • Report
  • 150 Pages
  • China
From
Squamous Non-Small Cell Lung Cancer Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Squamous Non-Small Cell Lung Cancer Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 99 Pages
  • Global
From
Lung Cancer Market - Global Forecast 2025-2032 - Product Image

Lung Cancer Market - Global Forecast 2025-2032

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.